RMD vs VMD
RMD: ResMed develops cloud-connected software platforms and digital devices for out-of-hospital care, spanning sleep apnea management, COPD treatment, and residential care operations. VMD: Viemed provides home-based respiratory, chronic care, and women's health services with clinical practitioners delivering therapy and equipment rental to patients across all 50 US states.
Side-by-side fundamentals
| Metric | RMD | VMD | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $192.91 | $11.92 | |
| Market cap as of 2026-07-23 | $28.2B | $456M | |
| P/E as of 2026-07-23 | 18.56 | 30.61 | RMD lower |
| PEG as of 2026-07-23 | 1.15 | 0.93 | VMD lower |
| Net margin as of 2026-07-23 | +27.4% | +5.2% | RMD higher |
| Gross margin as of 2026-07-23 | +61.6% | +57.6% | RMD higher |
| Operating margin as of 2026-07-23 | +34.2% | +8.2% | RMD higher |
| ROE as of 2026-07-23 | +24.4% | +10.7% | RMD higher |
| ROA as of 2026-07-23 | +18.0% | +7.6% | RMD higher |
| Debt / equity as of 2026-07-23 | 0.10 | 0.06 | VMD lower |
| Revenue growth (YoY) as of 2026-07-23 | +10.3% | +23.1% | VMD higher |
| Revenue CAGR (3y) SEC XBRL | +12.9% | +24.9% | VMD higher |
| Dividend yield as of 2026-07-23 | +1.2% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-07-23 | 0.76 | 1.12 | |
| 1-year return as of 2026-07-22 close | -27.9% | +83.4% | VMD higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.